Circio (CRNA.OL)

Executive Summary

Circio Holding ASA is a Norwegian biotechnology company pioneering circular RNA (circRNA) technology for next-generation gene and cell therapies. Its proprietary circVec platform enables sustained, high-level expression of therapeutic proteins by leveraging circularization of RNA, which enhances stability and reduces immunogenicity compared to linear mRNA. The company is initially targeting oncology and rare genetic diseases, with preclinical programs demonstrating proof-of-concept in in vivo models. Additionally, Circio maintains a legacy immuno-oncology asset, TG01, a RAS-targeting peptide vaccine that has shown immune responses in pancreatic cancer patients. With a strong IP portfolio and a seasoned management team, Circio is positioned to address key limitations in existing RNA therapeutics, such as short duration of expression and delivery challenges. The company trades on Oslo Børs under ticker CRNA.OL and has a market capitalization of approximately NOK 2.1 billion. Despite its innovative platform, Circio is still in early stages, with no products in clinical development beyond the legacy TG01 program. The circVec platform requires further validation through IND-enabling studies and eventual clinical trials, which carry significant technical and regulatory risks. The company's near-term value hinges on successful partnership deals or grants to fund its R&D pipeline. While the biotech sector has seen renewed interest in RNA modalities, Circio faces competition from both established mRNA companies and other circRNA-focused startups. Investors should monitor upcoming preclinical data releases and any strategic collaborations that could de-risk the platform and accelerate development. The company's cash runway is limited, making financing a key catalyst in the next 12–18 months.

Upcoming Catalysts (preview)

• Q1 2027Preclinical proof-of-concept data for circVec platform in a lead indication70% success
• H2 2026Partnership or licensing deal for circVec technology50% success
• Q4 2026Regulatory update or clinical trial application for TG01 or circVec40% success